Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Browne · SciRah

Researcher profile · Semantic Scholar

B. Browne

Share profile

B. Browne — researcher profile on SciRah

h-index: 16
Works: 49
Citations: 1,338

Most-cited papers

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
N. O'Brien, B. Browne, Lucy Chow, Yu-Hua Wang +6 more
2010Molecular Cancer Therapeutics338 citations Open access
Semantic Scholar
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
F. Hochgräfe, Lu-Xi Zhang, S. O'Toole, B. Browne +16 more
2010Cancer Research180 citations Open access
Semantic Scholar
HER-2 signaling and inhibition in breast cancer.
B. Browne, N. O'Brien, M. Duffy, J. Crown +1 more
2009Current Cancer Drug Targets130 citations
Semantic Scholar
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
B. Browne, J. Crown, N. Venkatesan, M. Duffy +3 more
2011Annals of Oncology103 citations Open access
Semantic Scholar
Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer
B. M. Ryan, N. O'Donovan, B. Browne, Caroline O'shea +5 more
2004British Journal of Cancer95 citations Open access
Semantic Scholar
Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway.
D. Croucher, F. Hochgräfe, Lu-Xi Zhang, Ling Liu +11 more
2013Cancer Research92 citations Open access
Semantic Scholar
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
S. Rani, C. Corcoran, L. Shiels, S. Germano +9 more
2014Cancer Research49 citations
Semantic Scholar
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
M. McDermott, B. Browne, N. Conlon, N. O'Brien +7 more
2014Molecular Cancer46 citations Open access
Semantic Scholar
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer
B. Browne, F. Hochgräfe, Jian-Min Wu, E. Millar +17 more
2013The FEBS Journal43 citations
Semantic Scholar
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
M. McDermott, N. Conlon, B. Browne, A. Szabo +5 more
2019Cancers42 citations Open access
Semantic Scholar
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
B. Browne, A. Eustace, S. Kennedy, N. O'Brien +11 more
2012Breast Cancer Research and Treatment41 citations
Semantic Scholar
Functional characterization of cancer-associated Gab1 mutations
C. Ortiz-Padilla, D. Gallego-Ortega, B. Browne, F. Hochgräfe +7 more
2013Oncogene39 citations
Semantic Scholar
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
A. Eustace, N. Conlon, M. McDermott, B. Browne +18 more
2018BMC Cancer26 citations Open access
Semantic Scholar
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
M. McDermott, A. Canonici, L. Ivers, B. Browne +4 more
2017International Journal of Oncology26 citations Open access
Semantic Scholar
Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation
Maria T. Abreu, William E. Hughes, K. Mele, R. Lyons +6 more
2011Molecular Biology of the Cell26 citations Open access
Semantic Scholar
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
A. Canonici, L. Ivers, N. Conlon, Kasper Pedersen +7 more
2018Investigational new drugs25 citations
Semantic Scholar
Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines.
A. Canonici, Kasper Pedersen, B. Browne, M. McDermott +3 more
20129 citations
Semantic Scholar
Inhibition of IGF 1 R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
B. Browne, J. Crown, N. Venkatesan, M. Duffy +3 more
20109 citations
Semantic Scholar
Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells.
M. McDermott, B. Browne, A. Szabo, J. Crown +1 more
20163 citations
Semantic Scholar
Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells.
M. McDermott, B. Browne, J. Crown, N. O'Brien +2 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar
The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistancein breast cancer
B. Browne
20093 citations
Semantic Scholar
Involvement of Lyn and the Atypical Kinase in a Basal Breast Cancer Signaling Pathway
D. Croucher, F. Hochgräfe, Lu-Xi Zhang, Ling Liu +12 more
20172 citations
Semantic Scholar
Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.
A. Eustace, B. Browne, S. Madden, L. O'Driscoll +6 more
20122 citations
Semantic Scholar
Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.
N. Conlon, M. McDermott, B. Browne, S. Roche +6 more
20181 citations
Semantic Scholar
14PAlterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model
N. Gaynor, M. Guibourdenche, B. Browne, L. O'Driscoll +4 more
20171 citations Open access
Semantic Scholar
HER2 Targeted Monoclonal Antibodies and Tyrosine Kinase Inhibitors
N. O'Brien, A. Canonici, K. Howe, M. McDermott +4 more
20141 citations Open access
Semantic Scholar
144 Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive Breast Cancer
A. Eustace, B. Browne, M. McDermott, P. O'Leary +6 more
20121 citations Open access
Semantic Scholar
145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer
M. McDermott, B. Browne, N. O'Brien, D. Slamon +6 more
20121 citations
Semantic Scholar
The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.
N. O'Brien, B. Browne, Lucy Chow, C. Ginther +6 more
20091 citations
Semantic Scholar
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
M. McDermott, B. Browne, N. Conlon, N. O'Brien +7 more
2023Molecular Cancer0 citations Open access
Semantic Scholar
Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer
N. Conlon, M. McDermott, B. Browne, S. Roche +7 more
2019Poster Session Abstracts0 citations
Semantic Scholar
Insulin-like growth factor I receptor (IGF-IR) inhibition in trastuzumab (T) resistant HER2+ breast cancer (BrCa) cells
B. Browne, J. Crown, N. Venkatesan, M. Pegram +4 more
20160 citations
Semantic Scholar
Abstract P4-07-06: miR-9 expression, retinoids and their potential role in trastuzumab resistance
K. Howe, B. Browne, Sinéad T. Aherne, J. Crown +1 more
20150 citations
Semantic Scholar
Neuromedin U: A Candidate Biomarker and Therapeutic Targetto Predict and Overcome Resistance to HER-Tyrosine
S. Rani, C. Corcoran, L. Shiels, S. Germano +9 more
20150 citations
Semantic Scholar
Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
B. Browne, A. Eustace, S. Kennedy, N. O'Brien +11 more
2014Breast Cancer Research and Treatment0 citations Open access
Semantic Scholar
Abstract 1826: Altered expression of miRNAs in acquired trastuzumab resistance
K. Howe, A. Eustace, G. Gullo, B. Browne +3 more
20140 citations
Semantic Scholar
Neuromedin U: A potential predictive biomarker for HER2-targeted drugs.
S. Rani, S. Germano, S. Madden, C. Corcoran +7 more
20120 citations Open access
Semantic Scholar
Microrna-9 and -224 In Trastuzumab Resistant HER2 Positive Breast Cancer Cells
K. Howe, A. Eustace, S. Souahli, B. Browne +5 more
20120 citations Open access
Semantic Scholar
143 MicroRNA-224 and −375 in Trastuzumab and Lapatinib Acquired and Innate Resistant HER2 Positive Breast Cancer Cells
K. Howe, A. Eustace, S. Souahli, B. Browne +5 more
20120 citations
Semantic Scholar
IGF1R and phosphorylated IGF1R in HER2-positive breast cancer.
B. Browne, J. Crown, A. Eustace, S. Kennedy +10 more
2011Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract 3131: A novel tyrosine kinase signaling pathway in human basal breast cancer
R. Daly, F. Hochgräfe, D. Croucher, Lu-Xi Zhang +4 more
20110 citations
Semantic Scholar
P5-06-09: Acquired Sensitivity to TRAIL Mediated Apoptosis in Lapatinib Resistant SKBR3 Cells.
A. Eustace, B. Browne, M. McDermott, C. Gallagher +3 more
20110 citations
Semantic Scholar
Abstract 4938: Extracellular miRNAs have potential as minimally-invasive biomarkers for predicting response to HER2-targeted agents, including Trastuzumab, as used in breast cancer
C. Corcoran, S. Rani, B. Browne, J. Crown +2 more
20110 citations
Semantic Scholar
Abstract 3633: eEF2 in acquired lapatinib resistance in HER2 positive breast cancer cells
M. McDermott, B. Browne, J. Crown, N. O'Brien +6 more
20100 citations
Semantic Scholar
Cancer esearch or and Stem Cell Biology sine Phosphorylation Profiling Reveals the Signaling R work Characteristics of Basal Breast Cancer Cells
Hochgräfe, Lu-Xi Zhang, S. O'Toole, B. Browne +16 more
20100 citations
Semantic Scholar
CAN-10-0911 Cancer esearch or and Stem Cell Biology sine Phosphorylation Profiling Reveals the Signaling R work Characteristics of Basal Breast Cancer Cells
Hochgräfe, Lu-Xi Zhang, S. O'Toole, B. Browne +16 more
20100 citations
Semantic Scholar
Abstract 613: Increased PI3K/AKT activity, which confers resistance to trastuzumab, can be overcome by lapatinib
N. O'Brien, Yu-Hua Wang, Lucy Chow, K. Wilcox +7 more
20100 citations
Semantic Scholar
Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells
B. Browne, J. Crown, N. Venkatesan, M. Pegram +4 more
20070 citations
Semantic Scholar
The role of Insulin-like Growth Factor I Receptor (IGF-IR) in Trastuzumab resistance in breast cancer cells
B. Browne, N. O'Donovan, N. Venkatesan, M. Pegram +4 more
20060 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. O'Donovan×38
Invite
N. O'Donovan — researcher profile on SciRah
J. Crown×34
Invite
J. Crown — researcher profile on SciRah
N. O'Brien×21
Invite
N. O'Brien — researcher profile on SciRah
M. McDermott×21
Invite
M. McDermott — researcher profile on SciRah

×12

Invite

A. Eustace — researcher profile on SciRah

Invite

D. Slamon — researcher profile on SciRah

Invite

M. Clynes — researcher profile on SciRah

Invite

S. Madden — researcher profile on SciRah

Invite

M. Duffy — researcher profile on SciRah

Invite

R. Daly — researcher profile on SciRah

L. O'Driscoll×8

Invite

L. O'Driscoll — researcher profile on SciRah

Invite

D. Croucher — researcher profile on SciRah